Promoter polymorphisms in the chitinase 3-like 1 gene influence the serum concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy subjects
Authors:
- Kaspar R NielsenKNKaspar R Nielsen
- Rudi SteffensenRSRudi Steffensen
- Martin BoegstedMBMartin Boegsted
- John BaechJBJohn Baech
- Soeren Lundbye-ChristensenSLSoeren Lundbye-Christensen
- Merete L HetlandMHMerete L Hetland
- Sophine B KrintelSKSophine B Krintel
- Hans E JohnsenHJHans E Johnsen
- Mette NyegaardMNMette Nyegaard
- Julia S JohansenJJJulia S Johansen
Open Access
- 29 June 2011
- journal article
- research article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 13 (3) , R109
Abstract
Introduction: The present study investigates the association between single nucleotide polymorphisms (SNPs) in the chitinase 3-like 1 (CHI3L1) gene and serum concentrations of YKL-40 in Danish patients with rheumatoid arthritis (RA) and healthy controls as well as the association with RA in the Danish population. The CHI3L1 gene is located on chromosome 1q32.1 and encodes the YKL-40 glycoprotein. YKL-40 concentrations are elevated in the serum of patients with RA compared to healthy subjects, and YKL-40 has been suggested to be an auto-antigen and may play a role in development of RA and in inflammation. Methods: Eight SNPs in the CHI3L1 gene and promotor were genotyped in 308 patients with RA and 605 controls (healthy blood donors) using TaqMan allele discrimination assays. Serum concentrations of YKL-40 were determined by an enzyme-linked immunosorbent assay (ELISA). Results: We found significant association between the serum concentrations of YKL-40 and polymorphism in the CHI3L1 gene among both patients with RA and controls. The g.-131(C > G) polymorphism (rs4950928) was most strongly associated with age adjusted serum concentrations of YKL-40 in patients with RA (P < 2.4e-8) and controls (P < 2.2e-16). No significant allelic- or genotypic association with RA was found in this Danish cohort. Conclusions: We suggest that the g.-131(C > G) promoter polymorphism has a substantial impact on serum concentrations of YKL-40 in patients with RA and healthy subjects. However, the polymorphism does not seem to confer risk to RA itself. The effect of CHI3L1 polymorphism on clinical outcome or the response to treatment in patients with RA remains to be investigated.Keywords
This publication has 53 references indexed in Scilit:
- Role of YKL-40 in the Angiogenesis, Radioresistance, and Progression of GlioblastomaJournal of Biological Chemistry, 2011
- DANBIO--powerful research database and electronic patient recordRheumatology, 2010
- The chitinase and chitinase-like proteins: a review of genetic and functional studies in asthma and immune-mediated diseasesCurrent Opinion in Allergy and Clinical Immunology, 2009
- Rheumatoid arthritisThe Lancet, 2009
- A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infectionJournal of Hepatology, 2009
- Effect of Variation inCHI3L1on Serum YKL-40 Level, Risk of Asthma, and Lung FunctionNew England Journal of Medicine, 2008
- Functional Variants in the Promoter Region of Chitinase 3–Like 1 (CHI3L1) and Susceptibility to SchizophreniaThe American Journal of Human Genetics, 2007
- SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism lociCell Research, 2005
- Evolving concepts of rheumatoid arthritisNature, 2003
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988